Evidence map›Paper›PMID 42449704›Full record

ArticleCancers2026

MKRN2-Mediated Degradation of IGF2BP3 Suppresses MYC and Enhances CDK4/6 Inhibitor Sensitivity in Bladder Cancer.

Qi Pan, Qing Shi, Yubo Zhao, Tianxi Yu, Shiyu Bai, Haoran Zhu, Wei Zhang, Yaowei Li, Ziyi Liu, Haonan Li and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Qi PanDepartment of Urology, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200080, China.
Qing ShiNHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China.
Yubo ZhaoDepartment of Urology, Second Affiliate Hospital of Harbin Medical University, Harbin 150001, China.
Tianxi YuNHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China.
Shiyu BaiDepartment of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin 150001, China.
Haoran ZhuNHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China.
Wei ZhangDepartment of Urology, Second Affiliate Hospital of Harbin Medical University, Harbin 150001, China.
Yaowei LiNHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China.
Ziyi LiuNHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China.
Haonan LiNHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China.
Ziqi WangNHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China.
Zhichao TongNHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China.

Funding

Excellent Youth Project of Heilongjiang Provincial Natural Science Foundation YQ2024H023Heilongjiang Province Postdoctoral Foundation LBH-Z22030National Natural Science Foundation of China 81902569National Natural Science Foundation of China 82572347National Natural Science Foundation of China 82573847The Harbin Medical University Cancer Hospital Haiyan Foundation JJZD2024-24The Nn10 project at the Affiliated Cancer Hospital of Harbin Medical University Nn102024-01
6 · The paper itself

Abstract

backgroundCDK4/6 inhibitors induce G1/S cell-cycle arrest in bladder cancer; however, adaptive resistance limits their therapeutic efficacy. The role of the m

methodsTranscriptomic profiling was performed in palbociclib-treated bladder cancer cell lines (T24, RT112, and UMUC-3) to identify m

resultsIGF2BP3 was identified as the only m

conclusionsThese findings establish the MKRN2-IGF2BP3-MYC axis as a critical regulator of CDK4/6 inhibitor sensitivity in bladder cancer. Targeting IGF2BP3 or enhancing MKRN2 activity may represent a promising strategy to overcome adaptive resistance and improve the therapeutic efficacy of CDK4/6 inhibitors.

Indexed as

bladder cancerCDK4/6 inhibitionIGF2BP3MKRN2MYCproliferation

Identifiers

PMID42449704
PMCPMC13359444

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.